• Hillcrest’s power inverter technology platform to offer efficiency and performance improvements
• Hillcrest inverter technology platform can be applied at nearly every stage of the electric ecosystem

Electrification is playing a prominent role in the global transition from fossil fuels to sustainable energy sources. As energy costs rise amid increased demand, Hillcrest Energy Technologies (CSE: HEAT) (OTCQB: HLRTF) (FRA: 7HIA.F) holds a vital key that unlocks performance and efficiency improvements throughout the entire electrification ecosystem. Hillcrest’s first application for its inverter technology is focused on the growing EV market. Hillcrest’s SiC high-efficiency traction inverter technology converts the DC output from the batteries into AC input used by the motor. The expected benefits of Hillcrest’s traction inverter have been confirmed via testing and shared in a technical white paper published earlier in 2022:

• Significant efficiency gains – 99%+ inverter efficiency
• Increased power density targeting 50 kW/L+
• Significantly increased motor efficiency
• Lower stress on mechanical and electrical parts/reliability
• Improved thermal management

Applications of Hillcrest’s technology extend beyond EV operation and charging to grid-connected power generation and energy storage systems. For example, the company’s inverter technology can convert wind turbine generation AC output to deliver power to a battery or deploy it to the grid. Power inverters can also be used in solar power generation by converting DC output from the photovoltaic panels into AC power that flows into the home, back to the battery, or out to the grid. Other applications include power conversion for energy storage systems and EV DC fast chargers. For these non-motorized applications, Hillcrest’s inverter technology has the potential to provide significant efficiency gains, better power quality and grid stability, lower stress on mechanical and electrical parts, and improved thermal management. “We set out to be a market leader in developing and deploying next-generation energy solutions,” said Ari Berger, Hillcrest CTO. “As technology-forward experts, we are uniquely positioned to execute to our vision and deliver high-efficiency inverter solutions that have the potential to revolutionize global electrification. We’ve already achieved inverter efficiencies exceeding 99% at switching frequencies up to 60 kHz – enabling further efficiency enhancements in the overall system, such as electric motors.  These accomplishments exceed any other inverter solutions we’ve seen on the market thus far. Moving forward, we will continue to strive for more groundbreaking improvements as we develop additional applications.” Based in Vancouver, British Columbia, Hillcrest develops transformative power conversion technologies and control system solutions for next-generation electrical systems. As the world moves forward on the path to sustainable energy sources, the company is favorably positioned to provide the keys that unlock performance and efficiency across the entire electrification value chain. For more information, visit the company’s website at www.HillcrestEnergy.tech. NOTE TO INVESTORS: The latest news and updates relating to HLRTF are available in the company’s newsroom at https://ibn.fm/HLRTF

• OPEC releases “bullish” forecast for oil demand moving into 2023
• Healthy global economic growth, improvements in geopolitical developments and containment of COVID-19 in China contribute to positive projection
• LRDC has leased 37,900 mineral acres in the Western Williston Basin of Montana

Despite a slowing economy and worries of a recession, the oil and gas industry has rebounded strongly throughout 2021, with oil prices reaching their highest levels in six years, a recent Deloitte report noted (https://ibn.fm/aobNZ); OPEC’s recent bullish 2023 forecast indicates that upward trend may continue. That’s good news for Laredo Oil (OTC: LRDC), an oil exploration and production company that is working to start drilling in Montana. “OPEC expects global oil demand to rise in 2023 but at a slower pace than 2022, the producer group said in its first forecast for next year, citing still robust economic growth and progress in containing COVID-19 in China,” reported Reuters (https://ibn.fm/wqA7A). “In a monthly report on Tuesday, the Organization of the Petroleum Exporting Countries (‘OPEC’) said it expects demand to rise by 2.7 million barrels per day (‘bpd’), or 2.7%, in 2023. It left this year’s growth forecast unchanged at 3.36 million bpd.” Reuters noted that oil use has “rebounded from the pandemic-induced slump in 2020 and is set to exceed 2019 levels this year. The outlook for 2023 suggests a strain on supplies could persist as growth in non-OPEC output, which has been hit by Russian losses, is expected to lag the rise in demand.” However, Reuters noted that OPEC pointed to “2023 expectations for healthy global economic growth amidst improvements in geopolitical developments, combined with expected improvements in the containment of COVID-19 in China” as factors in its projected positive oil forecast. Laredo Oil’s primary focus is on acquiring, developing and operating undervalued conventional oil and gas properties. The company is also engaged in the acquisition and development of select mature oil fields that are suitable for its proprietary Enhanced Oil Recovery (“EOR”) methods. The company leased 37,900 mineral acres in the Western Williston Basin of Montana at favorable prices during the most recent down cycle and continues to take leases in the area. For more information, visit the company’s website at www.Laredo-Oil.com. NOTE TO INVESTORS: The latest news and updates relating to LRDC are available in the company’s newsroom at https://ibn.fm/LRDC

• Lexaria is a global innovator of drug delivery platforms, including its patented DehydraTECH(TM) technology
• The company recently released information that would help its stakeholders research and understand how biotech and pharmaceutical companies are valued
• Based on some of the methodologies used in valuation, Lexaria is positioned favorably as its DehydraTECH-processed CBD for the treatment of hypertension has successfully reached the IND application stage, with the program recently receiving an additional boost
• The FDA agreed with Lexaria’s proposal to pursue a 505(b)(2) new drug application (“NDA”) regulatory pathway, an abbreviated pathway, for its hypertension program

As a follow-up to recent coverage by Zacks Small-Cap Research, which valued the company at $15.00 (https://ibn.fm/moh25), global innovator Lexaria Bioscience (NASDAQ: LEXX) provided information to its stakeholders that would help them conveniently research and understand different non-affiliated third-party sources and their methodologies for valuing biotech and pharmaceutical companies. “Valuation of equities is a complex task with innumerable risks and rewards that include far-reaching macro events as well as company-specific developments. It is nearly impossible to foresee all risks and rewards, but underlying logic-based evaluation is one way to provide a realistic framework of expectations that investors can use in their analysis,” the August 11 press release reads (https://ibn.fm/yrv8k). One of the logic-based evaluations considers the stage at which a company’s drug development program has reached. According to the U.S. Food and Drug Administration (“FDA”), there are five steps to the drug development process: Discovery and Development, Preclinical Research, Clinical Research, FDA Drug Review, and, finally, FDA Post-Market Drug Safety Monitoring. However, not more than about 250 of 5,000-10,000 compounds tested during the Discovery stage successfully transition to the third step. Against this backdrop, Lexaria stands out, having completed the first two steps with its DehydraTECH-CBD for hypertension treatment, with favorable results to boot. The company’s first advanced human clinical study (“HCS”) for hypertension, conducted in 2018, for example, showed that DehydraTECH drug delivery technology delivered 317% more CBD to the blood at 30 minutes. Later HCS’s evidenced rapid and sustained drop in blood pressure (HYPER-H21-1), up to a 23% average reduction in overnight blood pressure and reduced arterial stiffness (HYPER-H21-2), and a 41% overall reduction in pulmonary artery systolic pressure (“PASP”) in male subjects (HYPER-H21-3). Lexaria is set to announce results from its fourth HCS – HYPER-H21-4 – in Q4 2022 (https://ibn.fm/N5sjD). If the HYPER-H21-4 study were registered with the FDA, Lexaria notes, it would possibly be a Phase 1B or 2A study. This information lends color to the company’s valuation going by a guide prepared by Bay Bridge Bio, which notes that a company’s valuation increases as its drug development progresses from Phase 1 through Phase 3. For example, at the start of a Phase I trial, a biotech company’s valuation would be $88 million, a figure that would then rise to $248 million at the start of Phase 2 study, finally eclipsing the $1 billion mark to settle at $1.119 billion when the Phase III trial begins. The figures increase further following an FDA approval of the drug candidate. Considering the FDA’s recent confirmation that it agreed with Lexaria’s proposal to pursue a 505(b)(2) new drug application (“NDA”) regulatory pathway, an abbreviated pathway, the company’s accelerated drug development program for hypertension therapeutics could wend way to a multi-billion-dollar valuation in due course. The pharmaceutical industry is rife with examples of such possibilities. In March, for example, Pfizer Inc. (NYSE: PFE) completed the acquisition of clinical-stage company Arena Pharmaceuticals for a total consideration of $6.7 billion. At the time of the acquisition, Arena was expecting results for its Phase 3 trial undertaken to evaluate the safety and efficacy of the etrasimod drug candidate in patients with active ulcerative colitis (https://ibn.fm/uI4b5). As a December 2021 report by accounting firm PwC notes, big pharma is set to spend anywhere between $5 billion and $15 billion and, in some cases, as much as $50 billion in 2022 to purchase promising biotech companies and their IP, as they seek to bring on board in new drugs that can become serious revenue generators (https://ibn.fm/zCx4o). Such acquisitions attest that biotech companies with little to no revenue can still be worth billions. For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• Psilocybin is seeing a “research resurgence” focused on how the substance changes the brain’s connectivity patterns
• CYBN is leading the industry in developing proprietary psychedelic-based therapeutics
• The company’s lead investigational molecule has the potential to treat major depressive disorder and alcohol use disorder

The status of psilocybin is evolving as a result of mounting public acceptance and growing evidence that the substance delivers remarkable health benefits. Cybin (NEO: CYBN) (NYSE American: CYBN) is on the leading edge of this transformation, as the clinical-stage biopharmaceutical company focuses on progressing psychedelics to therapeutics by offering a new standard of care for mental-health disorders and improving patient outcomes. Psilocybin is undergoing a transformation. Numerous studies have reported positive findings using psilocybin “for treating depression as well as smoking and alcohol addiction, and for reducing anxiety in the terminally ill,” reported Scientific America (https://ibn.fm/Wx1Cv). “Ongoing and planned studies are testing the drug for conditions that include opioid dependence, PTSD and anorexia nervosa. This scientific interest, plus growing social acceptance, is contributing to legal changes in cities across the U.S.” The article provided a quick overview of the history of the substance, noting that “after a flurry of research in the 1950s and 1960s, psilocybin and all other psychedelics were abruptly banned, partly in response to their embrace by the counterculture. Following the 1971 United Nations Convention on Psychotropic Substances, psilocybin was classed in the U.S. as a Schedule I substance. The article quoted David Nutt, a neuropsychopharmacologist at Imperial College London, as saying: “It’s the worst censorship of research in history.” This “censorship” appears to be coming to an end as Nutt and others are leading a “research resurgence” focused on how psilocybin changes the brain’s connectivity patterns, including reducing connections within the usual networks while increasing links between less connected regions. “Just this year, a study showed that treatment involving psilocybin led to sustained network alterations, which seemed to correlate with reduced depression symptoms,” the article observed. “Two organizations are beginning final rounds of trials for psilocybin’s use for depression, which could lead to the substance’s first approval by the U.S. Food and Drug Administration.” Cybin is heavily involved in this resurgence of research. The company is leading the industry in developing proprietary psychedelic-based therapeutics, with a pipeline featuring three psychedelic molecules —CYB003, CYB004 and CYB005 — that are derived from CYBN’s novel drug-discovery platform (https://ibn.fm/4ZfwT). Cybin’s lead investigational molecule, CYB003, is a deuterated psilocybin analog derived from psilocybin, which is part of a family of molecules called indolamines that includes more common neurotransmitters, such as serotonin. The substance is designed to achieve less variability in plasma levels, faster onset of action, shorter duration of effect and potentially better tolerability for an overall better outcome for patients. CYB003 has the potential to effectively treat major depressive disorder (“MDD”) and alcohol use disorder (“AUD”) and is currently being evaluated in a phase 1/2a clinical trial. A deuterated dimethyltryptamine (“DMT”), CYB004 has been shown to exert its psychedelic effects by activating the 5-HT2A receptor. In its natural form, DMT is rapidly metabolized in the body, unstable and not orally bioavailable. However, preclinical studies indicate that the deuterated DMT can overcome these limitations and provide increased oral and pulmonary bioavailability, faster onset with lower doses, less patient variability, and better dose titration for fewer side effects and longer-acting desensitization of the serotonergic receptors. The company reports that CYB004, which is currently in a phase 1 in-human study, has the potential to effectively treat anxiety disorders. The company’s third substance is CYB005, which is a discovery-phase phenethylamine derivative with the potential to effectively treat neuroinflammation and psychiatric conditions. CYB005 is in preclinical development. For more information, visit the company’s website at www.Cybin.com. NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

• GMGI sets new bar for quarterly revenue, topping $9 million for first time
• The company currently has a string of 15 consecutive profitable quarters
• Golden Matrix is growing through international M&A activity and launching gaming products, including a new highly anticipated eSports platform

Tech stocks have rallied since the tech-laden Nasdaq hit a nearly two-year low in June. Most of the first half of the year was dominated by geopolitical drama, and international upheaval fueling recession concerns amid spiking inflation. None of that stopped Golden Matrix Group (NASDAQ: GMGI) from having its best revenue quarter ever, spearheaded by horizontal and vertical growth. Golden Matrix, a provider of turnkey and white label gaming platforms and content, hasn’t filed its 10-Q quarterly report with the Securities and Exchange Commission yet, but did provide some color to investors on its third quarter of fiscal 2022, which ran from May-July. The Las Vegas-based company logged record revenues exceeding $9 million in the quarter, an improvement of approximately 177% from $3.25 million in the comparable quarter of fiscal 2021. Meaningful progress in both its flagship business-to-business (“B2B”) division and new business-to-consumer (“B2C”) division undergirded the jump in revenue. GMGI CEO Brian Goodman called the record quarter “even more impressive when considering the impact of global economic headwinds and an unfavorable exchange rate throughout the quarter.” The strength of the U.S. dollar is important to Golden Matrix as the bulk of its customers are overseas, particularly Asia-Pacific as far as B2B clients. Golden Matrix has chosen not to foray into the byzantine U.S. market, with its software designed to decline requests coming from within the country to maintain strict compliance with U.S. law. At the end of the quarter, GMGI had about 635 operators and approximately 6.5 million registered users across all its traditional B2B gaming platforms. Internationally, GMGI’s GM-X System is the industry standard as a configurable and scalable gaming platform providing access to over 10,000 games from dozens of providers along with sophisticated analytics, retention tools, loyalty features, and more. Through GM-X, Golden Matrix offers an array of games, including slots, table games, live games, and sports. The company is also planning on expanding into the burgeoning eSports that is growing at a stunning 22% compound annual growth rate on its way to an estimated $12.5 billion by 2030. The new GMGI B2B eSports platform is expected to make its debut any time now. Record quarterly revenue has also been spurred on by Golden Matrix taking an 80 percent stake in RKings, the United Kingdom-based owner of a popular skill tournament platform operated in the U.K. and Ireland. RKings gives players an opportunity to win a bevy of products from jewelry to golf clubs to exotic cars and vacations. In the latest quarter, RKings’ B2C competitions engaged more than 46,000 new registered users. The company didn’t provide insight into EBITDA or net income in its recent news release, but investors surely will be looking forward to the regulatory filings to see if the string of profitable quarters – currently standing at 15 – continues. For more information, visit the company’s website at www.GoldenMatrix.com. NOTE TO INVESTORS: The latest news and updates relating to GMGI are available in the company’s newsroom at https://ibn.fm/GMGI

• Brain concussion injuries have commanded a new level of respect in recent years as military personnel, athletes and care center administrations seek remedies rather than simply encouraging people to “shake off” a hard hit to the head
• Odyssey Health is advancing clinical trials for its novel PRV-002 drug / device solution for treating concussion patients
• The company reported completion of four cohorts of testing for safety in human subjects in August, and is preparing to launch Phase II testing that will evaluate the product’s efficacy
• PRV-002 is administered intranasally where it can be taken up across the blood-brain barrier by the body, helping it to target the area where it is needed most with minimal expression in the blood’s circulation system

Medical solutions innovator Odyssey Health (OTC: ODYY) is preparing to launch Phase II clinical trial testing of its novel brain concussion therapy following successful outcomes in examining its drug’s safety. Odyssey’s PRV-002 combines a synthetic neurosteroid with an intranasal applicator device to deliver the drug in such a way that it will be taken up into the brain with minimal circulation through the blood system. The drug is lipophilic, which helps it to cross the blood-brain barrier where it needs to go to rapidly eliminate swelling and oxidative stress in the brain in order to maintain proper blood flow to critical parts of the organ. Odyssey Health has completed a series of lab animal tests involving the company’s proprietary solution and announced this month the successful completion of the first cohort of the multiple ascending dose portion of its Phase I clinical trial analyzing safety of the drug in human volunteers. The company is finishing up the final stage of its Phase I trial that involves administering high doses of the drug to human patients. Phase II will take a hard look at the efficacy of the drug product by looking at specific outcome measures. (https://ibn.fm/x4TP7). Concussions, also known medically as mild traumatic brain injury, or mTBI, have come to be taken more seriously in the general public in recent years, particularly as professional athletes have acknowledged a need to prioritize their recovery from significant head impacts over a desire to remain competitive. NASCAR driver Kurt Busch became one of the latest to acknowledge head injury concerns when he chose to sit out multiple races until he could be assured he was mentally as well as physically recovered from a qualifying round crash in late July. “Brain injury recovery doesn’t always take a linear path. I’ve been feeling well in my recovery, but this week I pushed to get my heart rate and body in a race simulation type environment, and it’s clear I’m not ready to be back in the race car,” Busch said when he announced he’d miss a fourth race (https://ibn.fm/2YLuF). “This was by far the hardest week emotionally because I do feel the progression of recovery, but racing requires an extreme physical and mental effort, and my body is not 100% able to sustain the intense race conditions.” Odyssey’s PRV-002 solution aims to eventually be approved for on-site administration at incidents where head injuries occur, such as at athletic competitions. Patients would be treated within the first minutes after the injury happens, allowing them to avoid swelling that might lead to long-term consequences. Currently there is no U.S. Food and Drug Administration (“FDA”)-approved medication for treating concussions, allowing Odyssey Health to state they are pursuing a novel solution to fulfill an unmet need for millions of people worldwide. The Phase II trial is expected to include military sites that sustain a high rate of concussion. “We need a treatment to prevent the long-term consequences of concussion as far too many of our Service Members are retiring with TBI disorders that lessen their quality of life,” Major General (Ret.) Jim Linder, the former chief of staff for the U.S. Special Operations Command, stated last month in addressing Odyssey’s testing program (https://ibn.fm/q3uBK).” For more information, visit the company’s website at www.OdysseyHealthInc.com. NOTE TO INVESTORS: The latest news and updates relating to ODYY are available in the company’s newsroom at https://ibn.fm/ODYY

• Over 30% of greenhouse emissions originate from households, making tackling them a matter of key importance within the global climate control agenda
• Recent trials with fossil-fuel free homes in Colorado and Massachusetts could help drive the transition towards renewable-based electricity sources
• GeoSolar Technologies’ SmartGreen(TM) Home solution seeks to leverage upon solar and geothermal energy to power homes, helping them lower carbon emissions whilst gaining energy self sufficiency
• Fiscal legislation has increasingly shifted towards the promotion of renewable energy sources for residential uses

The average monthly utility bill in the community of Arvada, Colorado is seven dollars. The community, a residential enclave situated midway between the cities of Boulder and Denver, has established itself as one of the greenest neighborhoods in the United States, powering its homes and businesses exclusively through a combination of solar and geothermal energy (https://ibn.fm/723Ic). With thirty percent of total greenhouse gases originating from households, addressing rising home emissions is a key priority within the global climate change agenda. It is also the challenge that GeoSolar Technologies (“GST”), a Colorado-based climate technology company, has sought to address through its proprietary SmartGreen(TM) Home system, which is designed to harness energy from the earth and sun to power and purify homes including Arvada’s 28 unit GEOS Neighborhood and automobiles without the use of fossil fuels. In early August, Massachusetts signed a major climate bill into law laying out the key initiatives designed to usher the state to its goal of achieving net-zero emissions by 2050. To get there, the state’s climate roadmap calls for widespread electrification of homes, primarily through the use of heat pumps that use electricity to heat and cool homes. To that end, the State Governor has mandated that 10 communities in the state will participate in a pilot program prohibiting the use of fossil fuels in new buildings and major renovations (https://ibn.fm/xnXBl). “Ultimately, we need to stop building with fossil fuels, and the easiest way to decarbonize our buildings is for them not to be carbon-full from the beginning,” said Amy Boyd, policy director of the clean energy advocacy group Acadia Center. “The more we keep building with fossil fuels, the harder it’s going to be.” GeoSolar Technologies has sought to position for exactly such a change, through the launch of their revolutionary SmartGreen(TM) Home system. In its bid to transform every aspect of the living experience for the better, GeoSolar’s proprietary technology seeks to harness both, the power of the sun and earth to fully electrify homes. From solar panels on roofs through to geothermal heat pumps which take advantage of the warmth of the earth’s core and advanced CERV 2 air purification systems designed to manage indoor air quality in an efficient and intelligent manner, the SmartGreen(TM) Home system has been designed to dramatically increase the energy efficiency of a conventional household. Ultimately, the technology will seek to void the need for a home to depend on carbon-powered utilities or face increasingly exorbitant energy costs subject to volatile fossil fuel commodity prices (https://www.geosolarplus.org/new-homes). GeoSolar Technologies has already successfully installed its revolutionary residential technology in multiple test homes across the state of Colorado, with tests revealing that households using the SmartGreen(TM) Home system boasted some of the most impressive energy efficiency ratings (https://ibn.fm/Ux503) in the sector. More importantly, GeoSolar’s SmartGreen(TM) Home energy solution will also help homeowners benefit from upcoming legislation designed to support the deployment of clean energy fuel sources within households. Recently, Colorado Governor Jared Polis launched the ‘Heath Beneath our Feet’ initiative, designed to examine the barriers and opportunities relating to the use of geothermal technology. Polis, who serves as the chair of the Western Governors Association, said he believes this could help bring Colorado to 100% renewable energy by 2040 (https://ibn.fm/1cloJ). “We don’t know what exactly [the renewable energy sector is] going to look like 10 years from now. But we know there’s extraordinarily promising opportunities. So, let’s do what we can now,” said Sen. Nick Hinrichsen, D-Pueblo. For more information, visit the company’s website at www.GeoSolarPlus.com. NOTE TO INVESTORS: The latest news and updates relating to GeoSolar Technologies are available in the company’s newsroom at https://ibn.fm/GST

• Various regions around the world are experiencing extreme heat waves, which have been attributed to climate change
• FuelPositive is guided by the understanding that the world needs sustainable, clean energy to replace fossil fuels that are responsible for the climate change phenomenon, and has developed a green ammonia production system
• The on-site, containerized green ammonia system is designed to produce ammonia from sustainable electricity, water and air with no carbon emissions
• The use of the system is aimed at reducing dependence on the energy-intensive Haber-Bosch process, which generates about 1.2% of the global CO2 emissions

The 2022 summer season in the northern hemisphere has been brutal. Marked by heat waves baking vast swathes of different continents, from the US-West and South-Central United States to the UK and China, the season has so far caused heaping helpings of discomfort, drought, wildfires, and power shortages. In mid-August, a heat wave settled in California, causing temperatures to cross the 100 degrees F (38 degrees C) mark. And with the scorching heat stretching power supplies to a breaking point as residents sought to cool down, the state asked residents and businesses to cut power use. But the concern was not just limited to the power supply. The heat raised the risk of wildfires and also prompted the US government to warn that more drastic cuts in water usage were needed to protect existing dwindling supplies in reservoirs (https://ibn.fm/3PIVT). Meanwhile, China is facing its fiercest heat wave in 60 years, with temperatures routinely crossing 40 degrees C (104 degrees F) in dozens of cities during August (https://ibn.fm/4lljN). And in the UK, forecasters are warning that temperatures will rise to mid-30 degrees C before the end of the month (https://ibn.fm/9ZH4s). At the center of these extreme conditions is human-caused climate change. FuelPositive (TSX.V: NHHH) (OTCQB: NHHHF), a company guided by the understanding that the world needs sustainable, clean energy to replace fossil fuels, is committed to developing and providing clean technologies that can reduce greenhouse gas emissions and fight climate change. One of these clean solutions, an on-site, modular, scalable green ammonia production system, is designed to use renewable electricity to produce green ammonia with no carbon emissions. The containerized system comprises an electrolyzer that produces hydrogen from water, a nitrogen generator that generates nitrogen from air, and an ammonia synthesis converter in which nitrogen and hydrogen react, forming green ammonia. This proprietary system provides one of the most environmentally benign processes for ammonia synthesis, solving the greenhouse gas emission problem associated with the traditional method of producing grey anhydrous ammonia, the Haber-Bosch process. The Haber-Bosch produces over 2.16 kilograms of carbon dioxide (“CO2”) equivalent per kilogram of ammonia (“kgCO2-eq/kg NH3”) and uses up high amounts of energy – over 30 GJ/ton of ammonia (https://ibn.fm/Fiy6Z). And considering the estimated global production of ammonia is roughly 150 million metric tons and is projected to rise by 2.3% annually, the greenhouse gas emissions are quite considerable. In fact, data shows that the Haber-Bosch process produces more than 450 million metric tons of CO2 every year, or about 1.2% of the global CO2 emissions (https://ibn.fm/hLwe8). Left unchecked, these emissions could further exacerbate an already dire situation that has seen states and countries experience ever-worsening heat waves. The issue of climate change is indeed a global phenomenon, and FuelPositive is playing an indelibly important role in reducing emissions. In addition to solving the emissions problem and, by extension, lessening the vagaries of climate change, the green ammonia system aims to address the worldwide shortage of ammonia and fertilizer. Being decentralized and containerized, the system provides on-site green-ammonia-production capabilities, enabling users to avoid relying on seriously compromised supply chains that are easily impacted by prevailing market forces and emerging issues, the most recent of which is Russia’s war in Ukraine. The FuelPositive system is also ideal for supplying nitrogen fertilizer for “controlled environment agriculture”, which includes greenhouses and vertical farming where plants are grown indoors. Because of damage caused by climate change and the precariousness of traditional farming, many sustainable farming experts believe controlled environment agriculture will play a key role in feeding the billions of people on the planet in the coming decades. As well as nitrogen fertilizer, FuelPositive’s system can provide that sector with some of the additional applications of its technology, including fossil fuel replacement, dehumidification, heating and cooling, (ammonia is commonly used as a refrigerant), as well as for water and system purification, and sanitizing. For more information, visit the company’s website at www.FuelPositive.com. NOTE TO INVESTORS: The latest news and updates relating to NHHHF are available in the company’s newsroom at https://ibn.fm/NHHHF

Financial institutions, Fintech industry leaders, regulators, banking institutions, companies, analysts, and investors are invited to attend FinovateFall 2022 being held this year at The Marriott Marquis Times Square, New York, NY. The attendees include the top 10 banks in the US and 275+ fintech institutions. Approximately 50% of attendees will hail from financial institutions. Witness the top innovations and trending ideas and meet the leading financial heads at the FinovateFall2022. The brightest minds in the financial and fintech sector will grace the occasion and impart sound strategies and insights about the latest industry trends. An impressive lineup of speakers awaits the attendees at the FinovateFall. Attendees can learn about the financial policies, upcoming financial trends, and the flow of the market to design future business policies. Witness 60+ demos on the main stage of the event, from various startups and finance companies on various topics ranging from blockchain, contracts, crypto, digital assets, compliance, reg tech, risk management, core banking, open banking, digital banking, digital transformation, financial inclusion, financial literacy, financial planning, financial crime, security, authentication, customer acquisition, customer engagement, embedded finance, payments, lending, and more. Young entrepreneurs and startups can leverage this networking opportunity to connect with the industry heavyweights of the Fintech spectrum. Sharing the floor of the FinovateFall event will be representatives of fintech, platform players, financial institutions, regulators, and investors, focused on re-defining the future of financial services. Attendees can engage with investors and industry leaders who can help them take their business forward. These networking sessions forge long-term business and personal relations. FinovateFall offers two opportunities for early-stage fintech/tech startups:

• Advanced Booster – Investor meetings. If you’re raising funding, this is your chance to connect with investors. The program comprises 10-minute meetings to make your pitch to early-stage investors.
• Startup Booster – Discounted pass. Meet the influencers and distinguished personas of the industry.

Attendees who are director/head/SVP/C-level from a financial institution can attend FinovateFall for free. The FinovateFall’s Leadership program is designed for banks, credit unions, insurance/reinsurance companies, and investment companies, to encourage networking for business relationships among industry players and businesses. The attendees can access the content on-demand for 12 months after the event. The sessions are available to access online a week after the event runs. To learn more, please visit https://ibn.fm/PX5z9.

• Backcountry flying is becoming increasingly popular, buoyed by growing enthusiasm among pilots, frequent events, and greater awareness through social media
• CubCrafters, a designer and manufacturer of backcountry aircraft, recently announced a public offering, through a Regulation A exemption, to raise capital that will go toward reducing order backlogs, bolster innovation, and expand production capacity
• The capital infusion will enable the company to better meet the expanding demand and serve the growing popularity of backcountry aviation. With a multi-year backlog of orders, increased capacity for aircraft production and support of the growing fleet is necessary
• Currently, CubCrafters offers over seven aircraft models in three certification categories, namely Part 23, Experimental/Amateur-Built (“E/A-B”), and Light Sport Aircraft

Backcountry flying is the biggest growth sector in light aviation, and Cub Crafters (typically styled CubCrafters), an OEM designer and manufacturer of backcountry aircraft, is positioning itself to tap into and accommodate this growth through a Regulation A public offering priced at $5 per share. With the capital infusion from the resulting investments, CubCrafters is looking to increase production, reduce manufacturing time (the company’s order backlog currently exceeds two years), foster innovation, and expand its reach in a rapidly growing industry. Also referred to as off-airport, bush, or outback flying, backcountry flying was once a niche segment and has only recently become a movement. It has a long standing legacy, as an article in the Plane&Pilot Magazine writes (https://ibn.fm/DgjGY), “It has been around since shortly after the Wrights first flew [the early 1900s], though it didn’t become a widespread activity until the era of the barnstormers [the 1920s], when planes got tough enough to take a little abuse.” This form of recreational grassroots flying characterized by pilots who fly their own planes for the many rewards of the experience, didn’t start to explode until about 25 years ago. The subsequent growth, the article notes, has been due to “a couple of events [that] have helped shine an even brighter light on the remarkable performance of a new generation of what are often highly modified short takeoff and landing (‘STOL’) planes, including a few that are of the pilot/builders’ own design.” In CubCrafters, enthusiast pilots find a partner for their pursuit of flight. It’s a company that shares and caters to their penchant for adventure by offering an array of aircraft available to be built at home, through a builder-assist option at the factory, and fully certified complete aircraft from the production line. Over it’s more than 40 years of existence, CubCrafters has established itself as a builder of different aircraft models in three certification categories: Federal Aviation Administration (“FAA”) certified, Experimental/Amateur-Built (“E/A-B”), and Light Sport Aircraft (“LSA”). Throughout its history, the company has continually focused on advancing from the origins of the classic Piper Super Cub, a legendary light utility aircraft famed for its bush flying and off-airport performance. “While our engineering has further improved STOL performance, we have also focused on improving every aspect that makes the Super Cub platform uniquely capable. The result is a range of modern adventure aircraft that are designed and engineered for backcountry flying. Pilots are rewarded with not only STOL performance, but also remarkable flight characteristics, uncommon comfort and ergonomics, unmatched range, and class-defining utility,” CubCrafters’ website reads (https://ibn.fm/8fIqZ). Currently, the company offers seven distinct models, the Carbon Cub SS, XCub, NXCub, Carbon Cub EX-2 and EX-3, and Carbon Cub FX-2 and FX-3. This lineup includes aircraft with a range of configurations from nosewheel or tailwheel landing gear, floats, and even skis. According to the company, this diverse product line appeals to every segment of the adventure aircraft market. CubCrafters also has a unique builder-assist program that lets pilots build their dream backcountry aircraft that perfectly aligns with their mission, under the watchful eye of the company’s staff and quality control system. With backcountry aviation growing in popularity globally, CubCrafters has witnessed record sales year after year as more and more pilots want to venture into remote locations. As Brad Damm, the company’s Vice President, described in a July 25 news release (https://ibn.fm/N62qx), that success, along with other achievements, is generally due to the company’s independent thinking and continued focus on innovation. CubCrafters is inviting investors, fans, and pilots to make reservations for its Regulation A offering. If the Securities and Exchange Commission (“SEC”) qualifies the offering, the reservations can be converted, allowing investors to own shares of preferred stock in the company. Reservations are non-binding and can be made through: www.ManhattanStreetCapital.com/CubCrafters. For more information, visit the company’s website at www.CubCrafters.com. NOTE TO INVESTORS: The latest news and updates relating to Cub Crafters Inc. are available in the company’s newsroom at https://ibn.fm/CUB